Lawsuit Alert: Investors who lost money with shares of Cardlytics, Inc. (NASDAQ: CDLX) should contact the Shareholders Foundation

An investor, who purchased shares of Cardlytics, Inc. (NASDAQ: CDLX), filed a lawsuit i over alleged violations of Federal Securities Laws by Cardlytics, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Cardlytics, Inc. (NASDAQ: CDLX) have certain options and for certain investors are short and strict deadlines running. Deadline: March 25, 2025. NASDAQ: CDLX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Atlanta, GA based Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. Cardlytics, Inc. reported that its annual Total Revenue rose from $298.54 million in 2022 to $309.2 million in 2023, and that its Net Loss declined from $465.26 million in 2022 to $134.7 million in 2023.

On August 7, 2024, Cardlytics, Inc. released its second quarter 2024 financial results, missing consensus estimates due to "slower-than-anticipated billings growth coupled with higher consumer incentives." Specifically, the Company stated that it had encountered "delivery issues" and "fast-paced changes to [its] technology platform" which led to "unpredictable delivery of the advertiser budgets."

Shares of Cardlytics, Inc. (NASDAQ: CDLX) declined from $15.88 per share on May 07, 2024, to as low as $2.89 per share on August 08, 2024.

The plaintiff claims that between March 14, 2024 and August 7, 2024, the Defendants failed to disclose to investors: (1) increasing consumer engagement led to an increase in consumer incentives; (2) that the Company could not increase its billings commensurate with the increased consumer engagement; (3) that, as a result, there was a significant risk that its revenue growth would slow or decline; (4) that the changes to ADE, which led to increased consumer engagement, led to the "under-delivery" of budgets and customers billing estimates; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Cardlytics, Inc. (NASDAQ: CDLX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.